TOTALLY LAPAROSCOPIC, MULTI-STAGE, RESTORATIVE PROCTOCOLECTOMY FOR INFLAMMATORY BOWEL DISEASES. A PROSPECTIVE STUDY ON SAFETY, EFFICACY AND LONG-TERM RESULTS.

Gianluca M Sampietro^{1,2}, Francesco Colombo², Alice Frontali^{2,7}, Caterina M Baldi², Stefania Carmagnola³, Andrea Cassinotti³, Alessandra Dell'Era³, Alessandro Massari³, Paola Molteni³, Dario Dilillo⁴, Paolo Fociani⁵, Massimo Tonolini⁶, Giovanni Maconi³, Paolo Fiorina^{8,9,10}, Fabio Corsi^{11,12}, Roberto Bianco⁶, Manuela Nebuloni⁵, Gianvincenzo Zuccotti^{4,9}, Sandro Ardizzone³, and Diego Foschi²

¹IBD Surgical Unit; ²Division of General Surgery; ³Division of Gastroenterology; ⁴Division of Pediatrics; ⁵Division of Pathology; ⁶Division of Radiology; ASST Fatebenefratelli – Sacco, "Luigi Sacco", Milan, Italy; ⁷Department of Colorectal Surgery, Pôle des Maladies de l'Appareil Digestif (PMAD), Assistance Publique – Hôpiteau de Paris (AP-HP), Beaujon Hospital, University Denis Diderot, Paris, France; ⁸Nephrology Division, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA; ⁹International Center for T1D, Pediatric Clinical Research Center Fondazione Romeo ed Enrica Invernizzi, Department of Biomedical and Clinical Science L. Sacco, University of Milan, Italy; ¹⁰Division of Endocrinology, ASST Sacco Fatebenefratelli-Sacco, Milan, Italy; ¹¹Surgery Department, Breast Unit, ICS Maugeri, Pavia, Italia; ¹²Department of Biomedical and Clinical Science L. Sacco, University of Milan, Italy;

Address for correspondence:

Gianluca M Sampietro, MD Unità Operativa di Chirurgia delle Malattie Infiammatorie Croniche Intestinali Dipartimento di Area Chirurgica – ASST Fatebenefratelli - Sacco. Ospedale "Luigi Sacco" – Polo Universitario, Milano (Italy) Via G.B. Grassi 74, 20157 Email: <u>gianluca.sampietro@unimi.it</u> Phone: +390239043561

Abstract

Background: Laparoscopic ileo-pouch-anal anastomosis (IPAA) has been reported as having low morbidity and several advantages.

Aims: To evaluate safety, efficacy and long-term results of laparoscopic IPAA, performed in elective or emergency settings, in consecutive unselected IBD patients.

Methods: All the patients received totally laparoscopic 2-stage (proctocolectomy and IPAA – stoma closure) or 3-stage (colectomy – proctectomy and IPAA – stoma closure) procedure according to their presentation.

Results: From July 2007 to July 2016, 160 patients entered the study. 50.6% underwent a 3-stage procedure and 49.4% a 2-stage procedure. Mortality and morbidity were 0.6% and 24.6%. Conversion rate was 3.75%. 8.7% septic complications were associated with steroids and Infliximab treatment (p=0.0001). 3-stage patients were younger (p=0.0001), with shorter disease duration (p=0.0001), minor ASA scores of 2 and 3 (p=0.0007), lower inflammatory index and better nutritional status (p=0.003 and 0.0001), fewer Clavien-Dindo's grade II complications (p=0.0001), reduced rates of readmission and reoperation at 90 days (p=0.03), and shorter hospitalization (p=0.0001), but with similar pouch and IPAA leakage, compared to 2-stage patients. 8 years pouch failure and definitive ileostomy were 5.1% and 3.7%.

Conclusion: A totally laparoscopic approach is safe and feasible, with very low mortality and morbidity rates and very low conversion rate, even in multi-stage procedures and high-risk patients.

Acknowledgments: This series included many patients who were under the care of Professor Gabriele Bianchi Porro and Professor Roberto de Franchis, the former Chiefs and Chairs of the Division of Gastroenterology, and thus their contributions are gratefully acknowledged. A special thought and a thank you to Professor Angelo Maria Taschieri.

1. Introduction

Restorative proctocolectomy with ileal pouch-anal anastomosis (IPAA) was first described by Parks and Nicholls in 1978, and it has since become the treatment of choice for familial adenomatous polyposis (FAP), ulcerative colitis (UC), indeterminate colitis (IC) and selected cases of Crohn's Disease (CD)¹⁻³. In inflammatory bowel disease (IBD), restorative proctocolectomy with IPAA is usually performed electively in one or two stages, depending on whether a temporary ileostomy is created. Abdominal colectomy is advocated prior to IPAA procedure in high-risk patients and in emergency settings².

Restorative proctocolectomy remains a highly technically demanding operation with reported perioperative morbidity and mortality rates of 15%-50% and 1%-13%, respectively⁴⁻¹⁰. Laparoscopy has been proposed as an appealing alternative to open surgery for IPAA, and it has been found to be associated with a reduction in post-operative complications, less intraoperative blood loss, earlier recovery, shorter length of hospitalization, reduction in visceral adhesions and incisional hernias, improved cosmesis, and better preservation of female fecundity, in comparison with open surgery¹¹⁻ ¹⁵. However, totally laparoscopic restorative proctocolectomy with IPAA, especially if performed in multiple stages, is a quite complex procedure, and few studies in tertiary centers have prospectively evaluated a totally laparoscopic approach, in elective or emergency settings, and in a consistent number of consecutive and unselected IBD patients¹⁶⁻²⁰.

The aim of the present study was to evaluate safety, efficacy and long-term results of totally laparoscopic, multi-stage IPAA, in a consecutive, unselected series of IBD patients referred to a tertiary Italian center.

2. Patients and Methods

A defined diagnostic, therapeutic and clinical care protocol (in Italian: Percorso Diagnostico Terapeutico Assistenziale – PDTA) was established in January 2008, to offer a high-quality standard of surgical care, in line with international guidelines, and to provide a management and accounting tool for auditing. A Multi-Disciplinary Team (MDT) for IBD was already present, involving gastroenterologists, surgeons, paediatricians, pathologists and radiologists. Oncologists, ophthalmologists and infectious disease specialists were also involved for selected cases. A dedicated service was also guaranteed by stoma-therapists, nutritionists, and psychologists. A 24-hour joint surgery and gastroenterology IBD on-call service was already available. In all patient candidates for emergency or elective surgery, a multi-disciplinary meeting (MDM) evaluation was performed, involving the surgical team that had an experience of performing more than 250 IPAA by open approach, as well as advanced training in laparoscopic colorectal surgery. A dedicated, prospective database was set up and approved by the ethics committee of our institution, including 75 variables concerning demographic, pre-operative, peri-operative, and long-term data. Follow-up was maintained with clinical examinations at 3, 6 and 12 months after surgery, and then yearly or in case of necessity. Functional results were evaluated at 12 months. All patients received an endoscopic control of the pouch at 12 months and then every 2 years or in case of necessity. Informed consent for the surgical procedures and data auditing was obtained from all patients after specific multidisciplinary counselling.

2.1. Emergency settings

Emergency surgery was indicated in all patients with severe acute colitis refractory to salvage therapy or with surgical complications (fulminant colitis, perforation, massive haemorrhage, toxic megacolon). Severe acute colitis was defined using the Truelove and Witts criteria, as reported in the European Crohn's and Colitis Organization (ECCO) and American Society of Colon and Rectal Surgeons (ASCRS) Guidelines^{2,21-26}. To exclude the risk for toxic dilation or to monitor response to therapy, a computed tomography (CT) scan and/or bowel ultrasound, instead of plain abdominal x-

ray, was performed in most cases^{27,28}. At hospital admission, all patients were evaluated jointly by a dedicated gastroenterologist and surgeon at most within 24 hours, based on clinical, biochemical and radiological examinations. Patients were considered as candidates for immediate surgical procedure or re-evaluation after rescue therapy with intravenous steroids at 72 hours, based on clinical history. Patients with an indication for second line medical treatment with cyclosporine or Infliximab were re-evaluated at the 5th, and no later than the 7th day. In the case of no improvement or worsening, surgery was performed in urgent or emergency settings by means of total abdominal colectomy, rectal closure, and Brooke's ileostomy^{2,29,30}.

2.2. Elective settings

Indications for elective surgery were chronic refractory colitis, complicated or refractory CD of the colon, chronic obstruction, and malignant transformation^{2,31}. For patients referred from other hospitals, a specific discussion with the proposing gastroenterologist or paediatrician was performed and the complete case reviewed, including reviewing previous biopsies from the referral pathologist (PF) when necessary. According to patient characteristics, restorative proctocolectomy was performed in 1, 2 or 3 stages. The 3-stage procedure consisted of abdominal colectomy and rectal closure with Brooke's ileostomy³⁰, followed by completion proctectomy, formation of IPAA and loop ileostomy, and ileostomy closure. The 3-stage procedure included also the elective completion proctectomy of those patients treated in the emergency setting by abdominal colectomy. The 2-stage procedure refers to a proctocolectomy with IPAA and loop ileostomy followed by closure of ileostomy. In the modified 2-stage and in the single-stage procedures ileostomy was omitted at time of restorative completion proctectomy and proctocolectomy respectively^{2,29,32-35}.

2.3. Study population

All consecutive patients referred to the IBD Surgical Unit for restorative proctocolectomy were considered eligible for the study. Candidate patients for open surgery due to previous major abdominal procedures or with contraindications to laparoscopy, and those treated by ileo-rectal anastomosis or proctocolectomy with definitive ileostomy, were not included. Previous open appendectomy, cholecystectomy, gynaecological and urological procedures were not considered as contraindications to the laparoscopic approach. Patients who required conversion during the first laparoscopic procedure were considered for an "intention to treat" analysis in terms of morbidity and mortality, but then excluded from analysis of the following step according to "per protocol" analysis. In the emergency setting, hemodynamically unstable or perforated patients were candidates for open colectomy and thus were excluded from the study². Toxic megacolon was not considered an absolute contraindication to laparoscopic colectomy. As previously reported and in accordance with European and North American Guidelines, aging was not considered itself a contraindication to laparoscopic restorative proctocolectomy^{2,24,36}. A complete record of each patient with pre-operative, intraoperative, post-operative and long-term results was entered in the data base. Readmission and reoperation were considered within 90 days. Conversion into laparotomy was defined as an unplanned abdominal incision longer than 6cm in any abdominal quadrant. Long-term results were recorded in terms of functional results at 12 months, and diagnosis of pouchitis, IPAA stenosis or fistulisation, and pouch failure during follow-up.

2.4. Surgical procedures

All patients were treated by a totally laparoscopic approach using a five-trocars technique (Figure 1). Vascular ligations were always performed at major trunks (inferior mesenteric artery and vein, middle-, right-, and ileo-colic vessels), from left side to right side, avoiding peri-visceral dissection, in order to minimize intestinal mucosal ischemia, with loss of barrier function, and consequent intraoperative systemic toxicity³⁷. The rectal stump was always managed with intra-corporeal stapling and overlock running suture. Total mesorectal excision (TME) and carcinogenic mesocolic excision were performed in the cases of dysplasia or colorectal cancer (CRC). Incomplete TME (I-TME), where the dissection was carried out in the pre-sacral plane posteriorly and close to the rectum in the anterior and lateral planes, was used in all other patients. All pouches were 15-18cm long, stapled J-pouch as designed by Utsunomiya in 1980³⁸. The ileo-pouch-anal anastomosis was performed by a Knight-Griffen³⁹, transanal anastomosis, using a circular end-to-end stapling device (CEEA), with

intraoperative measurement of the distance from the dentate line between 1cm and 2cm. A hand-sewn anastomosis, with transanal mucosectomy, was performed when necessary (low rectal dysplasia or CRC, failure of the CEEA stapler device)^{2,40}. Extraction of the specimen and pouch creation were performed through the site of the temporary ileostomy in the right iliac fossa, or through a periumbilical or a suprapubic incision, depending on the dimension of the specimen or the need for mesenteric lengthening of the pouch. In the patients undergoing the 3-stage procedure, the same ports and extraction site were used for abdominal colectomy (stage 1) and completion proctectomy with IPAA (stage 2) (Figure 1). The completion proctectomy with IPAA and loop ileostomy were performed between 3 and 6 months after abdominal colectomy, rectal closure and ileostomy. This time interval is based on the need to obtain adequate steroid tapering, desaturation from any pharmacological compounds, and normalization of nutritional status. Temporary ileostomy was closed at 6-8 weeks with a wide lumen, functional end-to-end, stapled anastomosis, after clinical examination. Control of the pouch and IPAA was performed by pelvic magnetic resonance imaging (MRI) prior to ileostomy closure only in selected cases with a clinical or biochemical suspicion of dehiscence.

2.5. Outcome measures

Perioperative mortality and morbidity were considered during hospital stay and within 90 days after each step of 1, 2 or 3-stage surgical procedures. Postoperative complications were classified using the Clavien-Dindo's classification⁴¹⁻⁴³. Major surgical complications were defined as Clavien-Dindo's grade III or IV, while grade V corresponds to mortality. Intra-abdominal septic complications (IASC), including pelvic sepsis, were particularly evaluated. Functional results were considered in terms of frequency of bowel movements over 24 hours, and diurnal and/or nocturnal soiling and/or incontinence, at 12 months after ileostomy closure. Long-term complications were defined as any adverse event related to the surgical procedure occurring during the follow-up. The minimum followup was 12 months. Pouchitis was defined as an inflammation of the pouch in the presence of symptoms associated with endoscopic and histopathologic findings². Pouch failure was defined as excision or indefinite defunctioning of the pouch². A comparison was performed between 2- and 3stage procedures in terms of cumulative early and late postoperative results referred to IPAA creation.

2.6. Statistical analysis

Comparison of proportions was performed using chi-square or Fisher's exact test where appropriate. Continuous variables were analysed using Student's t test. Long term pouch survival was calculated with the time-to-event Kaplan and Meier estimates. This study was approved and conducted according to the ethical standards of the ethics committee of our institution, and reported according to the Strengthening the Reporting of Observational Studies in Epidemiology [STROBE] guidelines⁴⁴.

Results

From January 2008 to December 2016, 204 patients entered the diagnostic, therapeutic and clinical care protocol (PDTA) at "Luigi Sacco" University Hospital. According to patient selection criteria, 44 patients were excluded from this survey: 20 patients (9.8%) were candidates for open surgery due to previous major laparotomy or clinical contraindications to pneumoperitoneum, 14 patients (8.7%) received an IRA or permanent ileostomy (78.5% of these patients were also treated by laparoscopy), and 10 patients (4.9%) were perforated or hemodynamically unstable and thus operated on using an open approach. The total percentage of patients considered unsuitable for the laparoscopic approach was 16.1% (of all 204 patients). In the remaining 160 patients, 231 major abdominal procedures and 136 ileostomy closures were performed. There were 100 males (62.5%), 13 patients (8.1%) presented extra-intestinal manifestations of IBD, 11 (6.8%) had a family history of IBD, 12 (7.5%) were active smokers, and 21 (13.1%) received a previous abdominal surgery. Preoperative diagnosis of UC was present in 153 patients (95.6%), CD in 4 (2.5%), and IC in 3 (1.9%), while 31 (19.3%) patients were operated on for dysplasia or CRC. The mean age at diagnosis was 38.1 ±16.3 years (min 5, max 80 years), the mean age at first-stage surgical procedure was 48 ± 16.1 years (min 15, max 82 years), and the mean disease duration was 10.1 ± 8.9 years. Disease extension was a pancolitis in 92.5% and a left-sided colitis or proctitis in 7.5%. 81 patients (50.6%) underwent a sub-total colectomy, 47 of them (58%) in the emergency setting due to severe acute colitis, 8 for toxic megacolon (9.9%), and the remaining 26 for poor clinical conditions (32.1%). One female patient died on post-operative day 2, after emergency colectomy, for *ictus cerebri* at the age of 80 years (mortality rate 1.2%). Three patients were converted to open surgery (conversion rate 3.7%), and 6 patients have not yet completed the following stages. Characteristics of the patients submitted to abdominal colectomy, rectal closure and ileostomy are reported in Table 1. Seventy-one patients received completion proctectomy and IPAA with a conversion rate of 2.8% (2 patients), and 5 of them (7.1%) without diversion by temporary ileostomy (modified 2-stage procedure). Seventy-nine patients (49.4%) were operated on by a 2-stage (72 patients -91.1%) or a single-stage procedure (7 patients -8.9%). The overall rate

of patients without diversion at the time of pouch and IPAA formation was 8% (7 single-stage + 5 modified 2-stage). Comparisons of patient characteristics at time of completion proctectomy or restorative proctocolectomy are reported in Table 2. Intra-abdominal septic complications (IASC), including pelvic sepsis, occurred in 14 patients (8.7%), 5 (6.2%) at the time of colectomy, 2 (2.8%) at the time of completion proctectomy, and 7 (8.8%) after proctocolectomy. Comparing patients with IASC with patients with other or no complications, 57.1% vs. 16.2% were treated with a combination of systemic steroids and Infliximab, 28.6% vs. 24.3% with systemic steroids alone, and 14.3% vs. 59.5% were being treated with another or no therapeutic regimen (p=0.0001).

The conversion rate in the 3-stage procedure (stage 1 + stage 2) was 3.3%, and in all single and multistage procedures was 3.75%. Complications at ileostomy closure are listed in Table 3. Mortality rate at 90 days in 1, 2, or 3-stage procedures was 0.6%. Long-term results and the cumulative probability of the first episode of pouchitis, pouch failure, and definite ileostomy are reported in Figure 2.

Discussion

A multidisciplinary approach, which includes formal multidisciplinary meetings and allows for integration of the contributions of all specialists necessary for adequate treatment of IBD patients, is of paramount importance for tertiary standard of care. Performing such a complex surgical PDTA requires significant design and organization, medical and nursing staff upgrading, and, above all, a change in mentality. A very aggressive policy in terms of early multidisciplinary discussions, re-evaluation and surgery is necessary to achieve low morbidity and mortality rates⁴⁵⁻⁴⁷. Success also depends upon prospective auditing of patients concerning timing and indication for surgery, intraoperative critical issues, perioperative complications, and long-term results, in order to verify results and update strategies⁴⁸. Selection criteria for patients who are candidates for laparoscopy for elective or emergency procedures are rarely reported in the literature. In this series, the patients were consecutive and unselected, and the only reason for an open procedure, apart from clinical contraindications, was previous major open abdominal surgery. Applying these criteria,

contraindication to laparoscopy was 16.1%, but conversion rate was very low (3.75%), considering that reported conversion rate in trials and observational studies ranges from 1 to $23\%^{49-56}$, and that conversion rate after laparoscopic cholecystectomy, the most popular laparoscopic procedure, is reported to be 5-10%⁵⁷. Emergency sub-total colectomy for acute colitis in IBD is a potentially lifethreatening procedure, with a reported mortality rate that ranges, in Europe and North America, from 1% to 13%^{4-6,46}. In 2006, the United Kingdom national audit of IBD identified a mortality rate of 2.1-4.7% after emergency colectomy⁴⁶. In 2012, Tottrup et al., in the Danish population-based nationwide cohort study of 2889 cases, showed a 30-day mortality of 5.2% after emergency colectomy and 0.9% after elective proctocolectomy for UC, and 8.1% and 1.5% for CD⁵. In 2015, an audit of 1166 patient from 237 French centers found a mortality rate of 1.5% (0-2.7%)^{6,58} after elective restorative proctocolectomy. However, the vast majority of patients in all these series were operated on in the 1990's, and in the early 2000's by open procedures. Only 8 studies reported on mortality after laparoscopic colectomy, with a rate of 0.25% in a total of 402 patients⁴⁷. The most important prognostic factors for mortality are the volume of the center, the surgeon's experience and the timing of surgery, given that high-volume centers (>10 cases per year), with dedicated surgeons and with aggressive surgical policies, have reported mortality rates around 2% for emergency surgery and 1% for elective surgery^{36,45-47,52,54,59-64}. Morbidity is subject to the same prognostic factors of mortality and remains quite high in almost all the series. Expected morbidity ranges from 25% to 65%, but major complications have shown a tendency to decrease over years, in particular after laparoscopic procedures performed in referral centers^{6,11,47,59,65}. In most studies, complications are reported as a description, limiting the possibility of adequate comparisons. Unfortunately, even if the Clavien-Dindo classification should be used, some specific limitations in the field of IBD are present⁴¹⁻⁴³. In fact, the Clavien-Dindo classification has been designed to provide grading of complications after elective abdominal surgery. Accordingly, any deviation from the normal postoperative course, such as prolonged ileus or simple wound infections, are classified as Grade 1 complications, while blood transfusion and total parenteral nutrition (TPN) are classified as Grade 2. However, these therapeutic

regimens are the daily clinical practice for IBD patients, both in emergency and some elective settings. As shown in Table 1, Grade I and II complications after colectomy are 58%, but if blood transfusions and TPN are excluded, these complications only make up 8.6%. Similarly, as shown in Table 2, they change from 32.9% to 6.3% after restorative proctocolectomy. Another limitation of the Clavien-Dindo classification is that it accounts only for complication during hospitalization. Readmission and reoperation after discharge, another common aspect of IBD patients, is rarely reported in surgical series and generally within 30 days^{7,66,67}. Extension of the observation period to 90 days is more indicative of the course of IBD patients⁴⁸. The vast majority of readmission and reoperation after colectomy and proctocolectomy are related to ileostomy complications (ileus, obstruction, dehydration and electrolyte imbalance). Some authors have proposed to omit diversion after ileal pouch surgery to avoid stoma-related complications, but at the cost of a 3-fold greater (5% to 15%) incidence of IPAA leakage and pouch-related sepsis⁶⁸⁻⁷². In the present series, the 5.3% cumulative incidence of leakage is quite low, with 8% of the patients without diversion. The 6% incidence of IASC was strongly related to treatment with steroids in association with Infliximab, as previously reported⁷³⁻⁷⁷. However, both leakage and IASC were independent of the number of surgical stages. Determining the right timing for restorative proctocolectomy and deciding on a single or a staged procedure remains the crucial issue of this surgery, since the majority of complications, including mortality, could be a consequence of this initial decision. To date, only 5 studies have focused on the comparison between the 2 and 3-stage approach: one from the same inventor of the pouch (RJ Nicholls)¹⁸, 3 with the series dating back to the 1980's¹⁸⁻²⁰, one with a laparoscopic approach in 17.4% of the cases (25 patients)⁷⁸, and only a recent one using the total laparoscopic approach in a consistent number of patients⁶⁵. Hicks et al. concluded in favour of the predominant use of 2-staged surgery, but the patients who underwent the 3-stage procedure in the study only totalled 28, and only 7 were treated by laparoscopy⁷⁸. Galandiuk et al. also favored 2 stages in their series of 871 patients, while Nicholls and Penna suggested the 3-stage procedure was safer, but all the patients were operated on by open surgery in the pre-anti-TNF era¹⁸⁻²⁰. The results from the group

of Clichy, who used laparoscopy in 100% of 185 patients, are very similar to the results in this study. in particular in terms of patient characteristics, operative findings, perioperative complications and postoperative results (Table 1 and 2). However, some interesting differences should be highlighted⁶⁵. A direct comparison of the 2- and 3-stage procedures is quite difficult as it involves different patients with different indications. However, focusing on the construction and anastomosis of the pouch, there are major differences between patients who have previously had a colectomy (who have passed the risks of surgery in emergency or in poor clinical conditions) and those who are candidates for proctocolectomy. In fact, the latter have a higher ASA score, an altered inflammatory and nutritional status, and most of them are receiving maximal medical treatment, as well as have a higher 90-day readmission and reoperation rate (Table 2). These results suggest that perhaps a subset of the patients who were candidates for proctocolectomy would have benefited from a staged procedure. Furthermore, a higher ASA score and longer hospitalization are still factors at the time of recanalization. However, no differences are present in terms of IPAA and pouch leakage. In the past, an attempt to reduce the number of procedures appeared to be indicated by the morbidity associated with multiple laparotomies, but in different surgical fields, such as cholecystectomy, bariatric surgery and gastroesophageal reflux disease, laparoscopy has changed the indications by reducing the morbidity in comparison with previous treatments.

In this context the proposal by some Authors to carry out a modified two-stage procedure, without diverting the patient at the time of completion proctectomy, appears very intriguing. In our experience only 7% of the patients underwent this procedure, but in the future the combination of a laparoscopic approach with a modified two-stage procedure should be studied in more depth³²⁻³⁵.

The possibility to perform a restorative proctocolectomy by a laparoscopic approach, with very low morbidity, morality, conversion rate and long-term results, regardless of the number of the stages, should allow for debate in the future about the possibility of having an evidence-based driven staging for IPAA surgery.

14

References

1. Parks AG, Nicholls RJ. Proctocolectomy without ileostomy for ulcerative colitis. British Medical Journal 1978;2:85-8.

2. Oresland T, Bemelman WA, Sampietro GM, et al. European evidence based consensus on surgery for ulcerative colitis. Journal of Crohn's & colitis 2015;9:4-25.

3. Panis Y, Poupard B, Nemeth J, Lavergne A, Hautefeuille P, Valleur P. Ileal pouch/anal anastomosis for Crohn's disease. Lancet 1996;347:854-7.

4. Pal S, Sahni P, Pande GK, Acharya SK, Chattopadhyay TK. Outcome following emergency surgery for refractory severe ulcerative colitis in a tertiary care centre in India. BMC Gastroenterol 2005;5:39.

5. Tottrup A, Erichsen R, Svaerke C, Laurberg S, Srensen HT. Thirty-day mortality after elective and emergency total colectomy in Danish patients with inflammatory bowel disease: a population-based nationwide cohort study. BMJ Open 2012;2:e000823.

6. Teeuwen PH, Stommel MW, Bremers AJ, van der Wilt GJ, de Jong DJ, Bleichrodt RP. Colectomy in patients with acute colitis: a systematic review. Journal of Gastrointestinal Surgery 2009;13:676-86.

7. Coakley BA, Telem D, Nguyen S, Dallas K, Divino CM. Prolonged preoperative hospitalization correlates with worse outcomes after colectomy for acute fulminant ulcerative colitis. Surgery 2013;153:242-8.

8. Fazio VW, Kiran RP, Remzi FH, et al. Ileal pouch anal anastomosis: analysis of outcome and quality of life in 3707 patients. Annals of surgery 2013;257:679-85.

9. Bernstein CN, Blanchard JF, Houston DS, Wajda A. The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory bowel disease: a population-based cohort study. Thromb Haemost 2001;85:430-4.

10. Fazio VW, Ziv Y, Church JM, et al. Ileal pouch-anal anastomoses complications and function in 1005 patients. Annals of surgery 1995;222:120-7.

11. Fleming FJ, Francone TD, Kim MJ, Gunzler D, Messing S, Monson JR. A laparoscopic approach does reduce short-term complications in patients undergoing ileal pouch-anal anastomosis. DisColon Rectum 2011;54:176-82.

12. Bartels SA, Vlug MS, Henneman D, Ponsioen CY, Tanis PJ, Bemelman WA. Less adhesiolysis and hernia repair during completion proctocolectomy after laparoscopic emergency colectomy for ulcerative colitis. Surgical endoscopy 2012;26:368-73.

13. Bartels SA, D'Hoore A, Cuesta MA, Bensdorp AJ, Lucas C, Bemelman WA. Significantly increased pregnancy rates after laparoscopic restorative proctocolectomy: a cross-sectional study. Annals of surgery 2012;256:1045-8.

14. Beyer-Berjot L, Maggiori L, Birnbaum D, Lefevre JH, Berdah S, Panis Y. A Total Laparoscopic Approach Reduces the Infertility Rate After Ileal Pouch-Anal Anastomosis: A 2-Center Study. AnnSurg 2013.

15. Hull TL, Joyce MR, Geisler DP, Coffey JC. Adhesions after laparoscopic and open ileal pouch-anal anastomosis surgery for ulcerative colitis. BrJSurg 2012;99:270-5.

16. Ouassi M, Lefevre JH, Bretagnol F, Alves A, Valleur P, Panis Y. Laparoscopic 3-step restorative proctocolectomy: comparative study with open approach in 45 patients. . Surg Laparosc Percutan Tech 2008;18:357-62.

17. Lefevre JH, Bretagnol F, Ouassi M, Taleb P, Alves A, Panis Y. Total laparoscopic ileal pouchanal anastomosis: prospective series of 82 patients. Surgical endoscopy 2009;23:166-73.

18. Nicholls RJ, Holt SD, Lubowski DZ. Restorative proctocolectomy with ileal reservoir. Comparison of two-stage vs. three-stage procedures and analysis of factors that might affect outcome. Diseases of the Colon & Rectum 1989;32:323-6.

19. Galandiuk S, Pemberton JH, Tsao J, Ilstrup DM, Wolff BG. Delayed ileal pouch-anal anastomosis. Complications and functional results. Diseases of the Colon & Rectum 1991;34:755-8.

20. Penna C, Daude F, Parc R, et al. Previous subtotal colectomy with ileostomy and sigmoidostomy improves the morbidity and early functional results after ileal pouch-anal anastomosis in ulcerative colitis. Diseases of the Colon & Rectum 1993;36:343-8.

21. Truelove SC, Witts LJ. Cortisone in ulcerative colitis; preliminary report on a therapeutic trial. British Medical Journal 1954;2:375-8.

22. Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. British Medical Journal 1955;2:1041-8.

23. Truelove SC, Witts LJ. Cortisone and corticotrophin in ulcerative colitis. British Medical Journal 1959;1:387-94 %U <u>http://www.ncbi.nlm.nih.gov/pubmed/13618646</u>.

24. Ross H, Steele SR, Varma M, et al. Practice parameters for the surgical treatment of ulcerative colitis. Diseases of the colon and rectum 2014;57:5-22.

25. Stange EF, Travis SP, Vermeire S, et al. European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Definitions and diagnosis. Journal of Crohn's & colitis 2008;2:1-23.

26. Dignass A, Eliakim R, Magro F, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. Journal of Crohn's & colitis 2012;6:965-90.

27. Parente F, Molteni M, Marino B, et al. Are colonoscopy and bowel ultrasound useful for assessing response to short-term therapy and predicting disease outcome of moderate-to-severe forms of ulcerative colitis?: a prospective study. American Journal of Gastroenterology 2010;105:1150-7.

28. Parente F, Molteni M, Marino B, et al. Bowel ultrasound and mucosal healing in ulcerative colitis. Dig Dis 2009;27:285-90.

29. Spinelli A, Sampietro GM, Bazzi P, Sacchi M, Montorsi M. Surgical approach to ulcerative colitis: when is the best timing after medical treatment? Curr Drug Targets 2011;12:1462-6.

30. Brooke BN. The management of an ileostomy, including its complications. Lancet 1952;2:102-4.

31. Travis SP, Stange EF, Lemann M, et al. European evidence-based Consensus on the management of ulcerative colitis: Current management. Journal of Crohn's & colitis 2008;2:24-62.

32. Sahami S, Bartels SA, D'Hoore A, et al. A Multicentre Evaluation of Risk Factors for Anastomotic Leakage After Restorative Proctocolectomy with Ileal Pouch-Anal Anastomosis for Inflammatory Bowel Disease. Journal of Crohn's & colitis 2016;10:773-8.

33. Swenson BR, Hollenbeak CS, Poritz LS, Koltun WA. Modified two-stage ileal pouch-anal anastomosis: equivalent outcomes with less resource utilization. Diseases of the Colon & Rectum 2005;48:256-61.

34. de Montbrun SL, Johnson PM. Proximal diversion at the time of ileal pouch-anal anastomosis for ulcerative colitis: current practices of North American colorectal surgeons. Diseases of the Colon & Rectum 2009;52:1178-83.

35. Samples J, Evans K, Chaumont N, Strassle P, Sadiq T, Koruda M. Variant Two-Stage Ileal Pouch-Anal Anastomosis: An Innovative and Effective Alternative to Standard Resection in Ulcerative Colitis. Journal of the American College of Surgeons 2017;224:557-63.

36. Colombo F, Sahami S, de Buck Van Overstraeten A, et al. Restorative Proctocolectomy in Elderly IBD Patients: A Multicentre Comparative Study on Safety and Efficacy. Journal of Crohn's & colitis 2017;11:671-9.

37. Vlug MS, Diepenhorst GM, van Koperen PJ, et al. Intestinal barrier function in patients undergoing colectomy. Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland 2011;13:1432-7.

38. Utsunomiya J, Iwama T, Imajo M, et al. Total colectomy, mucosal proctectomy, and ileoanal anastomosis. Diseases of the Colon & Rectum 1980;23:459-66.

39. Griffen FD, Knight CD, Sr., Whitaker JM, Knight CD, Jr. The double stapling technique for low anterior resection. Results, modifications, and observations. Annals of surgery;211:745-51; discussion 51-2.

40. Colombo F, Sahami S, de Buck Van Overstraeten A, et al. Restorative Proctocolectomy in Elderly IBD Patients: A Multicentre Comparative Study on Safety and Efficacy. Journal of Crohn's & colitis 2016.

41. Clavien PA, Sanabria JR, Strasberg SM. Proposed classification of complications of surgery with examples of utility in cholecystectomy. Surgery 1992;111:518-26.

42. Clavien PA, Barkun J, de Oliveira ML, et al. The Clavien-Dindo classification of surgical complications: five-year experience. Annals of surgery 2009;250:187-96.

43. Dindo D, Demartines N, Clavien P-A. Classification of Surgical Complications. Annals of surgery 2004;240:205-13.

44. von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007;370:1453-7.

45. Alves A, Panis Y, Bouhnik Y, Maylin V, Lavergne-Slove A, Valleur P. Subtotal colectomy for severe acute colitis: a 20-year experience of a tertiary care center with an aggressive and early surgical policy. Journal of the American College of Surgeons 2003;197:379-85.

46. Randall J, Singh B, Warren BF, Travis SP, Mortensen NJ, George BD. Delayed surgery for acute severe colitis is associated with increased risk of postoperative complications. The British journal of surgery 2010;97:404-9.

47. Bartels SA, Gardenbroek TJ, Ubbink DT, Buskens CJ, Tanis PJ, Bemelman WA. Systematic review and meta-analysis of laparoscopic versus open colectomy with end ileostomy for non-toxic colitis. The British journal of surgery 2013;100:726-33.

48. Morar PS, Hollingshead J, Bemelman W, et al. Establishing Key Performance Indicators [KPIs] and Their Importance for the Surgical Management of Inflammatory Bowel Disease-Results From a Pan-European, Delphi Consensus Study. Journal of Crohn's & colitis 2017;11:1362-8.

49. Baek SJ, Dozois EJ, Mathis KL, et al. Safety, feasibility, and short-term outcomes in 588 patients undergoing minimally invasive ileal pouch-anal anastomosis: a single-institution experience. Tech Coloproctol 2016;20:369-74.

50. Chung TP, Fleshman JW, Birnbaum EH, et al. Laparoscopic vs. open total abdominal colectomy for severe colitis: impact on recovery and subsequent completion restorative proctectomy. Diseases of the colon and rectum 2009;52:4-10.

51. El-Gazzaz GS, Kiran RP, Remzi FH, Hull TL, Geisler DP. Outcomes for case-matched laparoscopically assisted versus open restorative proctocolectomy. The British journal of surgery 2009;96:522-6.

52. Fichera A, Silvestri MT, Hurst RD, Rubin MA, Michelassi F. Laparoscopic restorative proctocolectomy with ileal pouch anal anastomosis: a comparative observational study on long-term functional results. Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 2009;13:526-32.

53. Goede AC, Reeves A, Dixon AR. Laparoscopic restorative proctocolectomy: a 10-year experience of an evolving technique. Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland 2011;13:1153-7.

54. Gu J, Stocchi L, Remzi FH, Kiran RP. Total abdominal colectomy for severe ulcerative colitis: does the laparoscopic approach really have benefit? Surgical endoscopy 2014;28:617-25.

55. Hata K, Kazama S, Nozawa H, et al. Laparoscopic surgery for ulcerative colitis: a review of the literature. Surgery today 2015;45:933-8.

56. Buchs NC, Bloemendaal ALA, Wood CPJ, et al. Subtotal colectomy for ulcerative colitis: lessons learned from a tertiary centre. Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland 2017;19:O153-o61.

57. Sakpal SV, Bindra SS, Chamberlain RS. Laparoscopic cholecystectomy conversion rates two decades later. JSLS 2010;14:476-83.

58. Parc Y, Reboul-Marty J, Lefevre JH, Shields C, Chafai N, Tiret E. Restorative Proctocolectomy and Ileal Pouch-anal Anastomosis. Annals of surgery 2015;262:849-53; discussion 53-4.

59. Buskens CJ, Sahami S, Tanis PJ, Bemelman WA. The potential benefits and disadvantages of laparoscopic surgery for ulcerative colitis: A review of current evidence. Baillieres Best Pract Res Clin Gastroenterol 2014;28:19-27.

60. Holder-Murray J, Zoccali M, Hurst RD, Umanskiy K, Rubin M, Fichera A. Totally laparoscopic total proctocolectomy: a safe alternative to open surgery in inflammatory bowel disease. Inflammatory bowel diseases 2012;18:863-8.

61. de Zeeuw S, Ahmed Ali U, Donders RA, Hueting WE, Keus F, van Laarhoven CJ. Update of complications and functional outcome of the ileo-pouch anal anastomosis: overview of evidence and meta-analysis of 96 observational studies. International journal of colorectal disease 2012;27:843-53.

62. Gu J, Stocchi L, Remzi F, Kiran RP. Factors associated with postoperative morbidity, reoperation and readmission rates after laparoscopic total abdominal colectomy for ulcerative colitis. Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland 2013;15:1123-9.

63. Larson DW, Cima RR, Dozois EJ, et al. Safety, feasibility, and short-term outcomes of laparoscopic ileal-pouch-anal anastomosis: a single institutional case-matched experience. Annals of surgery 2006;243:667-70; discussion 70-2.

64. Marceau C, Alves A, Ouaissi M, Bouhnik Y, Valleur P, Panis Y. Laparoscopic subtotal colectomy for acute or severe colitis complicating inflammatory bowel disease: a case-matched study in 88 patients. Surgery 2007;141:640.

65. Mege D, Figueiredo MN, Manceau G, Maggiori L, Bouhnik Y, Panis Y. Three-stage Laparoscopic Ileal Pouch-anal Anastomosis Is the Best Approach for High-risk Patients with Inflammatory Bowel Disease: An Analysis of 185 Consecutive Patients. Journal of Crohn's & colitis 2016;10:898-904.

66. Telem DA, Vine AJ, Swain G, et al. Laparoscopic subtotal colectomy for medically refractory ulcerative colitis: the time has come. Surgical endoscopy 2010;24:1616-20.

67. White I, Jenkins JT, Coomber R, Clark SK, Phillips RK, Kennedy RH. Outcomes of laparoscopic and open restorative proctocolectomy. The British journal of surgery 2014;101:1160-5.

68. Remzi FH, Fazio VW, Gorgun E, et al. The outcome after restorative proctocolectomy with or without defunctioning ileostomy. Diseases of the Colon & Rectum 2006;49:470-7.

69. Gorfine SR, Gelernt IM, Bauer JJ, Harris MT, Kreel I. Restorative proctocolectomy without diverting ileostomy. Diseases of the Colon & Rectum 1995;38:188-94.

70. Lovegrove RE, Tilney HS, Remzi FH, Nicholls J, Fazio V, Tekkis P. To divert or not to divert: A retrospective analysis of variables that influence ileostomy omission in ileal pouch surgery. Arch Surg 2011;146:82-8.

71. Weston-Petrides GK, Lovegrove RE, Tilney HS, et al. Comparison of outcomes after restorative proctocolectomy with or without defunctioning ileostomy. Arch Surg 2008;143:406-12.

72. Tjandra JJ, Fazio VW, Milsom JW, Lavery IC, Oakley JR, Fabre JM. Omission of temporary diversion in restorative proctocolectomy--is it safe? Diseases of the Colon & Rectum 1993;36:1007-14.

73. Subramanian V, Saxena S, Kang JY, al. E. Preoperative steroid use and risk of postoperative complications in patients with inflammatory bowel disease undergoing abdominal surgery. The American journal of gastroenterology 2008;103:2373-81.

74. Ferrante M, D'Hoore A, Vermeire S, et al. Corticosteroids but not infliximab increase shortterm postoperative infectious complications in patients with ulcerative colitis. Inflammatory bowel diseases 2009;15:1062-70.

75. Selvasekar CR, Cima RR, Larson DW, et al. Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis. Journal of the American College of Surgeons 2007;204:956-62; discussion 62-3.

76. Mor IJ, Vogel JD, da Luz Moreira A, Shen B, Hammel J, Remzi FH. Infliximab in ulcerative colitis is associated with an increased risk of postoperative complications after restorative proctocolectomy. Diseases of the colon and rectum 2008;51:1202-7; discussion 7-10.

77. Gu J, Remzi FH, Shen B, Vogel JD, Kiran RP. Operative strategy modifies risk of pouchrelated outcomes in patients with ulcerative colitis on preoperative anti-tumor necrosis factor-alpha therapy. Diseases of the colon and rectum 2013;56:1243-52.

78. Hicks CW, Hodin RA, Bordeianou L. Possible overuse of 3-stage procedures for active ulcerative colitis. JAMA surgery 2013;148:658-64.

Table 1. Patients submitted to abdominal colectomy, rectal closure and ileostomy [[¶]Clavien-Dindo's complications of grade I and II excluding perioperative blood transfusion and total parenteral nutrition (TPN)].

Age44 ± 17 yearsGenderMales50 (61,7%)Females31 (39,3%)Extra-intestinal Manifestations of IBD8 (9,8%)Familiarity for IBD4 (4,9%)Smoking Habit6 (7,4%)Ulcerative Colitis76 (93,8%)DiagnosisCrohn's DiseaseAge at Diagnosis (years)37,8 ± 16,5 yearsDisease Duration (years)6 ± 6,47 yearsAge at Diagnosis (years)6 ± 6,47 yearsDisease Duration (years)6 ± 6,47 yearsPrevious Abdominal Surgery8 (9,8%)Preoperative Therapy5-ASASteroids26 (32%)Combined Therapy17 (21%)Biologics26 (32%)Cyclosporine7 (8,8%)Preoperative Blood ExamsC Reactive Protein (mg/dL)Hatemaglobin (g/dL)10,3 ± 1,99White Cell Count (u/L)9411 ± 3670C Reactive Protein (mg/dL)5,55 ± 0,85Albumin (g/L)28 ± 6,7Transthyretine (g/L)0,14 ± 0,05Refractory to Medical Therapy26 (32,1%)Indication for SurgerySevere Acute ColitisAlbumin (g/L)28 ± 6,7Transthyretine (g/L)0,14 ± 0,05Conversion Rate3 (3,7%)Specimen DeliverySurgrapublic IncisionArefactory to Madical Therapy26 (32,1%)Conversion Rate3 (3,7%)Surgrapublic Incision37 (45,6%)Specimen DeliveryStora SiteComplications (Clavien-Dindo)IIIBIIIA3 (3,8%) <th>Number of patients</th> <th></th> <th>81</th>	Number of patients		81
TestTest 1.1 / YearsGenderMales50 (61,7%)Females31 (39,3%)Extra-intestinal Manifestations of IBD8 (9,8%)Familiarity for IBD4 (4,9%)Smoking Habit6 (7,4%)DiagnosisCrohn's DiseaseCrohn's Disease2 (2,4%)Indeterminate Colitis3 (3,8%)Age at Diagnosis (years)37,8 ± 16,5 yearsDisease Duration (years)6 ± 6,47 yearsAge at Diagnosis (years)37,8 ± 16,5 yearsDisease Duration (years)6 ± 6,47 yearsASA ScoreASA1ASA261 (75,3%)ASA310 (12,4%)Previous Abdominal Surgery8 (9,8%)Steroids2 6 (32%)Combined Therapy17 (21%)Biologics2 6 (32%)Cobined Therapy17 (21%)Biologics2 6 (32%)Cyclosporine7 (8,8%)Preoperative Blood ExamsCreactive Protein (mg/dL)Nation for SurgerySevere Acute ColitisRefractory to Medical Therapy26 (32,1%)Indication for SurgerySevere Acute ColitisRefractory to Medical Therapy26 (32,1%)Operative Time (minutes)211 ± 60,6Conversion Rate3 (3,7%)Specimen DeliveryStorma SiteAt the Materian Acute Colitis37 (45,6%)Specimen DeliveryStorma SiteAt the Materian Acute Colitis37 (45,6%)Complications (Clavien-Dindo)IIIBIIIA3 (3,8%)	Аде		$\frac{31}{10000000000000000000000000000000000$
Gender Females 31 (39,3%) Extra-intestinal Manifestations of IBD 8 (9,8%) Familiarity for IBD 4 (4,9%) Smoking Habit 6 (7,74%) Diagnosis Crohn's Disease 2 (2,4%) Age 44 ± 17 years Age 44 ± 17 years Age 44 ± 17 years Disposis (years) 37,8 ± 16,5 years Disease Duration (years) 6 ± 6,47 years Disease Duration (years) 6 ± 6,47 years ASA Score ASA1 10 (12,4%) Previous Abdominal Surgery 8 (9,8%) 5 Preoperative Therapy Combined Therapy 17 (21%) Biologics 26 (32%) 26 (32%) Cyclosporine 7 (8,8%) 7 Preoperative Therapy Combined Therapy 17 (21%) Biologics 26 (32%) 26 (32%) Cyclosporine 7 (8,8%) 7 Preoperative Blood Exams Total Proteins (g/L) 10,3 ± 1,99 White Cell Count (u/L) 9,41 ± 0,05 26 (32,1%) Conterist	<u></u>	Males	50 (61 7%)
Extra-intestinal Manifestations of IBD \$1 (93,3%) Familiarity for IBD 4 (4,9%) Smoking Habit 6 (7,4%) Diagnosis Crohn's Disease 2 (2,4%) Indeterminate Colitis 76 (93,8%) Age 44 ± 17 years Age at Diagnosis (years) 3 (3,8%) Disease Duration (years) 6 ± 6,47 years ASA Score ASA1 ASA Score ASA2 ASA3 10 (12,3%) Steroids 26 (32%) Previous Abdominal Surgery 8 (9,8%) Steroids 26 (32%) Preoperative Therapy Combined Therapy Biologics 26 (32%) Cyclosporine 7 (8,8%) Preoperative Blood Exams C Reactive Protein (mg/dL) Matematic (g/L) 10,3 ± 1,99 White Cell Count (u/L) 9411 ± 3670 C Reactive Protein (mg/dL) 41,2 ± 45,7 Total Proteins (g/L) 0,14 ± 0,05 Refractory to Medical Therapy 26 (32,1%) Indication for Surgery Severe Acute Colitis 47 (58%) <td>Gender</td> <td>Females</td> <td>31 (39 3%)</td>	Gender	Females	31 (39 3%)
Late intervalue statuties of induced $0 (5,8^{o})$ Familiarity for IBD $4 (4,9\%)$ Smoking HabitUlcerative Colitis $76 (93,8\%)$ DiagnosisCrohn's Disease $2 (2,4\%)$ Indeterminate Colitis $3 (3,8\%)$ Age 44 ± 17 yearsAge at Diagnosis (years) $37,8 \pm 16,5$ yearsDisease Duration (years) $6 \pm 6,47$ yearsASA ScoreASA110 (12,3\%)ASA ScoreASA2ASA ScoreASA310 (12,4%)Previous Abdominal Surgery $8 (9,8\%)$ S-ASA $5 (6,2\%)$ Steroids $26 (32\%)$ Combined Therapy $10,3 \pm 1,99$ White Cell Count (u/L) 9411 ± 3670 C Reactive Protein (mg/dL) $10,3 \pm 1,99$ White Cell Count (u/L) 9411 ± 3670 C Reactive Protein (mg/dL) $41,2 \pm 45,7$ Transthyretine (g/L) $0,14 \pm 0,05$ Refractory to Medical Therapy $26 (32,\%)$ Conversion Rate $3 (3,7\%)$ Operative Time (minutes) $211 \pm 60,6$ Conversion Rate $3 (3,7\%)$ Suprapublic Incision $37 (45,6\%)$ Specimen DeliveryStoma SiteStoma Site $42 (51,8\%)$ Precomplications (Clavien-Dindo)IIIB2 (2,4\%) 114	Extra-intestinal Manifestations of IRD		2 (0 2%)
Tormitry for itop $4 (4, 5, 8)$ Smoking Habit 6 (7, 4%) Diagnosis Crohn's Disease $2 (2, 4\%)$ Age 44 ± 17 years Age 44 ± 17 years Age at Diagnosis (years) 37,8 ± 16,5 years Disease Duration (years) 6 ± 6,47 years Disease Duration (years) 6 ± 6,47 years ASA Score ASA1 10 (12,3%) ASA Score ASA2 61 (75,3%) Previous Abdominal Surgery 8 (9,8%) 10 (12,4%) Previous Abdominal Surgery 5-ASA 5 (6,2%) Steroids 26 (32%) 26 (32%) Cyclosporine 7 (8,8%) 10 (3 ± 1,99) White Cell Count (u/L) 9411 ± 3670 C Reactive Protein (mg/dL) 10,3 ± 1,99 White Cell Count (u/L) 9411 ± 3670 C Reactive Protein (mg/dL) 41,2 ± 45,7 Total Proteins (g/L) 0,5 ± 6,7 Transthyretine (g/L) 0,14 ± 0,05 Refractory to Medical Therapy 26 (32,1%) Indication for Surgery Severe Acute Colitis 47 (58%) Toxic Megacolon 8 (9,9%) <td colspan="2"></td> <td>0 (3,0%) A (A Q%)</td>			0 (3,0%) A (A Q%)
Sinternal $0 (f/42)$ DiagnosisUlcerative Colitis76 (93,8%)DiagnosisCrohn's Disease2 (2,4%)Indeterminate Colitis3 (3,8%)Age44 ± 17 yearsAge at Diagnosis (years) $37,8 \pm 16,5$ yearsDisease Duration (years) $6 \pm 6,47$ yearsASA $10 (12,3%)$ ASA ScoreASA2ASA $10 (12,3%)$ ASA $10 (12,3%)$ ASA $10 (12,4%)$ Previous Abdominal Surgery $8 (9,8%)$ Steroids $26 (32%)$ Combined Therapy $17 (21%)$ Biologics $26 (32%)$ Corobined Therapy $17 (21%)$ Biologics $26 (32%)$ Cyclosporine $7 (8,8%)$ Haemoglobin (g/dL) $10,3 \pm 1,99$ White Cell Count (u/L) 9411 ± 3670 Preoperative Blood ExamsC Reactive Protein (mg/dL)Alburnin (g/L) $28 \pm 6,7$ Transtyretine (g/L) $0,14 \pm 0,05$ Indication for SurgerySevere Acute ColitisSpecimen DeliveryStoma SiteAlburnin (g/L) $21 \pm 60,6$ Conversion Rate $3 (3,7%)$ Specimen DeliveryStoma SiteHall $47 (58%) - 7 (8,6%)^{*}$ Specimen DeliveryStoma SiteAlburant (Clavien-Dindo)IIIAIIIA $3 (3,8%)$			4 (4,3%) 6 (7,4%)
Diagnosis Crehn's Disease 2 (2,4%) Indeterminate Colitis 3 (3,8%) Age 44 ± 17 years Age at Diagnosis (years) 37,8 ± 16,5 years Disease Duration (years) 6 ± 6,47 years ASA 10 (12,3%) ASA 10 (12,3%) ASA 5 (6,2%) Previous Abdominal Surgery 8 (9,8%) 5-ASA 5 (6,2%) Preoperative Therapy Combined Therapy Biologics 26 (32%) Preoperative Therapy Combined Therapy Preoperative Blood Exams C Reactive Protein (mg/dL) Preoperative Blood Exams C Reactive Protein (mg/dL) Preoperative Blood Exams Refractory to Medical Therapy 26 (32,1%) Severe Acute Colitis 40 min (g/L) 28 ± 6,7 Transthyretine (g/L) 0,14 ± 0,05 Refractory to Medical Therapy 26 (32,1%) Indication for Surgery Severe Acute Colitis Specimen Delivery Stora Site 49,9%) Operative Time (minutes) 211 ± 60,6 Conversion	Smoking Habit	Ulasvativa Calitia	
DiagnosisCroin's Disease22222222222222222222333<	Diagnosis	Orcerative Colltis	76 (93,8%)
Age44 ± 17 yearsAge at Diagnosis (years)37,8 ± 16,5 yearsDisease Duration (years)6 ± 6,47 yearsASA ScoreASA1ASA ScoreASA2ASA ScoreASA3ASA310 (12,3%)Previous Abdominal Surgery8 (9,8%)Preoperative Therapy5-ASASteroids26 (32%)Combined Therapy17 (21%)Biologics26 (32%)Cyclosporine7 (8,8%)Preoperative Blood ExamsC Reactive Protein (mg/dL)Haemoglobin (g/dL)0,3 ± 1.99White Cell Count (u/L)9411 ± 3670C Reactive Protein (mg/dL)10,3 ± 4,97Total Proteins (g/L)5,56 ± 0,85Albumin (g/L)28 ± 6,7Transthyretine (g/L)0,14 ± 0,05Refractory to Medical Therapy26 (32,1%)Operative Time (minutes)211 ± 60,6Conversion Rate3 (3,7%)Specimen DeliveryStora Site42 (51,8%)7 (58%)Peri-umbilical2 (2,6%)IIIA3 (3,8%)Complications (Clavien-Dindo)IIIBV4V4	Diagnosis	Cronn's Disease	2 (2,4%)
Age 44 1 / Years Age at Diagnosis (years) 37,8 ± 16,5 years Disease Duration (years) 6 ± 6,47 years ASA 10 (12,3%) ASA Score ASA2 ASA 61 (75,3%) ASA No. Previous Abdominal Surgery 8 (9,8%) Steroids 26 (32%) Preoperative Therapy Combined Therapy Biologics 26 (32%) Cyclosporine 7 (8,8%) Haemoglobin (g/dL) 10,3 ± 1,99 White Cell Count (u/L) 9411 ± 3670 C Reactive Protein (mg/dL) 41,2 ± 45,7 Total Proteins (g/L) 5,5 6 ± 0,85 Albumin (g/L) 28 ± 6,7 Transthyretine (g/L) 0,14 ± 0,05 Refractory to Medical Therapy 26 (32,1%) Indication for Surgery Severe Acute Colitis Toxic Megacolon 8 (9,9%) Operative Time (minutes) 211 ± 60,6 Conversion Rate 3 (3,7%) Specimen Delivery Stora Site 42 (51,8%) Peri-umbilical 2 (2,6%) Grade I+II 47 (58%) – 7 (8,6%) [¶]		Indeterminate Colitis	
Age at Diagnosis (years) $37,8 \pm 16,5 \ years$ Disease Duration (years) $6 \pm 6,47 \ years$ ASA 10 (12,3%) ASA Score ASA2 ASA 10 (12,3%) ASA 10 (12,3%) Previous Abdominal Surgery $80,8\%$ Previous Abdominal Surgery $80,8\%$ Steroids 26 (32%) Preoperative Therapy Combined Therapy Biologics 26 (32%) Cyclosporine 7 (8,8%) Haemoglobin (g/dL) 10,3 ± 1,99 White Cell Count (u/L) 9411 ± 3670 C Reactive Protein (mg/dL) 41,2 ± 45,7 Total Proteins (g/L) 5,5 6 ± 0,85 Albumin (g/L) 28 ± 6,7 Transthyretine (g/L) 0,14 ± 0,05 Refractory to Medical Therapy 26 (32,1%) Indication for Surgery Severe Acute Colitis 47 (58%) Toxic Megacolon 8 (9,9%) Operative Time (minutes) 211 ± 60,6 Conversion Rate 3 (3,7%) 3 (3,7%) 3 (3,7%) Specimen Delivery Storma Site 42 (51,8%) 7 (8,6%) [¶] IIIA <t< td=""><td>Age</td><td></td><td>44 ± 17 years</td></t<>	Age		44 ± 17 years
Disease Duration (years) $6 \pm 6,47$ years ASA Score ASA1 10 (12,3%) ASA Score ASA2 61 (75,3%) ASA3 10 (12,4%) Previous Abdominal Surgery 8 (9,8%) Previous Abdominal Surgery 8 (9,8%) 5 Preoperative Therapy Combined Therapy 17 (21%) Biologics 26 (32%) Cyclosporine 7 (8,8%) Preoperative Blood Exams Haemoglobin (g/dL) 10,3 ± 1,99 White Cell Count (u/L) 9411 ± 3670 C C Reactive Protein (mg/dL) 41,2 ± 45,7 Total Proteins (g/L) 5,56 ± 0,85 Albumin (g/L) 28 ± 6,7 Transthyretine (g/L) 0,14 ± 0,05 Refractory to Medical Therapy 26 (32,1%) Severe Acute Colitis 47 (58%) Operative Time (minutes) 211 ± 60,6 Conversion Rate 3 (3,7%) Specimen Delivery Stoma Site 42 (51,8%) Peri-umbilical 2 (2,6%) Grade I+II 47 (58%) - 7 (8,6%)* IIIA 3 (3,8%) Complications (Clavien-Dindo)	Age at Diagnosis (years)		37,8 ± 16,5 years
ASA Score ASA1 10 (12,3%) ASA Score ASA2 61 (75,3%) ASA3 10 (12,4%) Previous Abdominal Surgery 8 (9,8%) 5-ASA 5 (6,2%) Steroids 26 (32%) Preoperative Therapy Combined Therapy 17 (21%) Biologics 26 (32%) Cyclosporine 7 (8,8%) Preoperative Blood Exams Haemoglobin (g/dL) 10,3 ± 1,99 White Cell Count (u/L) 9411 ± 3670 C C Reactive Protein (mg/dL) 41,2 ± 45,7 Total Proteins (g/L) 5,56 ± 0,85 Albumin (g/L) 28 ± 6,7 Transthyretine (g/L) 0,14 ± 0,05 Refractory to Medical Therapy 26 (32,1%) Severe Acute Colitis 47 (58%) Operative Time (minutes) 211 ± 60,6 Conversion Rate 3 (3,7%) Specimen Delivery Stora Site 42 (51,8%) Peri-umbilical 2 (2,6%) Grade I+II 47 (58%) - 7 (8,6%)* IIIA 3 (3,8%) Complications (Clavien-Dindo) IIIB 2 (2,4%)	Disease Duration (years)		6 ± 6,47 years
ASA Score ASA2 61 (75,3%) (12,4%) Previous Abdominal Surgery 8 (9,8%) Preoperative Therapy 5-ASA 5 (6,2%) Steroids 26 (32%) Preoperative Therapy Combined Therapy 17 (21%) Biologics 26 (32%) Cyclosporine 7 (8,8%) Haemoglobin (g/dL) 10,3 ± 1,99 White Cell Count (u/L) 9411 ± 3670 C Reactive Protein (mg/dL) 41,2 ± 45,7 Total Proteins (g/L) 5,56 ± 0,85 Albumin (g/L) 28 ± 6,7 Transthyretine (g/L) 0,14 ± 0,05 Refractory to Medical Therapy 26 (32,1%) Indication for Surgery Severe Acute Colitis 47 (58%) Toxic Megacolon 8 (9,9%) Operative Time (minutes) 211 ± 60,6 Conversion Rate 3 (3,7%) Specimen Delivery Stoma Site 42 (51,8%) Prei-umbilical 2 (2,6%) Grade I+II 47 (58%) - 7 (8,6%) [¶] IIIA 3 (3,8%) 2 (2,4%) 10		ASA1	10 (12,3%)
ASA310 (12,4%)Previous Abdominal Surgery8 (9,8%)Preoperative Therapy5-ASASteroids26 (32%)Preoperative TherapyCombined TherapyBiologics26 (32%)Cyclosporine7 (8,8%)Haemoglobin (g/dL)10,3 ± 1,99White Cell Count (u/L)9411 ± 3670C Reactive Protein (mg/dL)41,2 ± 45,7Total Proteins (g/L)5,56 ± 0,85Albumin (g/L)28 ± 6,7Transthyretine (g/L)0,14 ± 0,05Refractory to Medical Therapy26 (32,1%)Indication for SurgerySevere Acute Colitis47 (58%)70kl = 0,66Conversion Rate3 (3,7%)Specimen DeliveryStoma Site42 (51,8%)2(2,6%)IIIA3 (3,8%)Complications (Clavien-Dindo)IIIB2(2,4%)IIIBVV	ASA Score	ASA2	61 (75,3%)
Previous Abdominal Surgery8 (9,8%)Preoperative Therapy5-ASA5 (6,2%)Preoperative TherapyCombined Therapy17 (21%)Biologics26 (32%)Cyclosporine7 (8,8%)Preoperative Blood ExamsHaemoglobin (g/L)10,3 ± 1,99White Cell Count (u/L)9411 ± 3670C Reactive Protein (mg/dL)41,2 ± 45,7Total Proteins (g/L)5,56 ± 0,85Albumin (g/L)28 ± 6,7Transthyretine (g/L)0,14 ± 0,05Refractory to Medical Therapy26 (32,1%)Indication for SurgerySevere Acute Colitis47 (58%)70xic MegacolonOperative Time (minutes)211 ± 60,6Conversion Rate3 (3,7%)Specimen DeliveryStoma Site42 (51,8%)2(2,6%)Grade I+II47 (58%) - 7 (8,6%)*IIIA3 (3,8%)Complications (Clavien-Dindo)IIIBU/V10		ASA3	10 (12,4%)
$\begin{array}{c c} \begin{array}{c} 5-ASA & 5 (6,2\%) \\ Steroids & 26 (32\%) \\ \hline \\ Combined Therapy & 17 (21\%) \\ Biologics & 26 (32\%) \\ \hline \\ Cyclosporine & 7 (8,8\%) \\ \hline \\ Haemoglobin (g/dL) & 10,3 \pm 1,99 \\ \hline \\ White Cell Count (u/L) & 9411 \pm 3670 \\ \hline \\ C Reactive Protein (mg/dL) & 41,2 \pm 45,7 \\ \hline \\ Total Proteins (g/L) & 5,56 \pm 0,85 \\ \hline \\ Albumin (g/L) & 28 \pm 6,7 \\ \hline \\ Transthyretine (g/L) & 0,14 \pm 0,05 \\ \hline \\ Refractory to Medical Therapy & 26 (32,1\%) \\ \hline \\ Indication for Surgery & Severe Acute Colitis & 47 (58\%) \\ \hline \\ \hline \\ Conversion Rate & 3 (3,7\%) \\ \hline \\ Specimen Delivery & Stoma Site & 42 (51,8\%) \\ \hline \\ Peri-umbilical & 2 (2,6\%) \\ \hline \\ Complications (Clavien-Dindo) & IIIB & 2 (2,4\%) \\ \hline \end{array}$	Previous Abdominal Surgery		8 (9,8%)
Steroids26 (32%)Preoperative TherapyCombined Therapy17 (21%)Biologics26 (32%)Cyclosporine7 (8,8%)Haemoglobin (g/dL)10,3 ± 1,99White Cell Count (u/L)9411 ± 3670C Reactive Protein (mg/dL)41,2 ± 45,7Total Proteins (g/L)5,56 ± 0,85Albumin (g/L)28 ± 6,7Transthyretine (g/L)0,14 ± 0,05Indication for SurgerySevere Acute Colitis47 (58%)Toxic MegacolonOperative Time (minutes)211 ± 60,6Conversion Rate3 (3,7%)Specimen DeliveryStoma Site42 (51,8%)7 (86%) - 7 (8,6%)*IIIA3 (3,8%)Complications (Clavien-Dindo)IIIB2 (2,4%)10		5-ASA	5 (6,2%)
Preoperative TherapyCombined Therapy Biologics17 (21%) 26 (32%) CyclosporinePreoperative Blood ExamsHaemoglobin (g/dL) White Cell Count (u/L)10,3 ± 1,99 9411 ± 3670Preoperative Blood ExamsC Reactive Protein (mg/dL) Total Proteins (g/L)41,2 ± 45,7 5,56 ± 0,85 Albumin (g/L)Indication for SurgeryRefractory to Medical Therapy Severe Acute Colitis26 (32,1%) 		Steroids	26 (32%)
$\begin{array}{c c} Biologics & 26 (32\%) \\ \hline Cyclosporine & 7 (8,8\%) \\ \hline Haemoglobin (g/dL) & 10,3 \pm 1,99 \\ \hline White Cell Count (u/L) & 9411 \pm 3670 \\ \hline C Reactive Protein (mg/dL) & 41,2 \pm 45,7 \\ \hline Total Proteins (g/L) & 5,56 \pm 0,85 \\ \hline Albumin (g/L) & 28 \pm 6,7 \\ \hline Transthyretine (g/L) & 0,14 \pm 0,05 \\ \hline Refractory to Medical Therapy & 26 (32,1\%) \\ \hline Indication for Surgery & Severe Acute Colitis & 47 (58\%) \\ \hline Toxic Megacolon & 8 (9,9\%) \\ \hline Operative Time (minutes) & 211 \pm 60,6 \\ \hline Conversion Rate & 3 (3,7\%) \\ \hline Specimen Delivery & Stoma Site & 42 (51,8\%) \\ \hline Peri-umbilical & 2 (2,6\%) \\ \hline Grade I+II & 47 (58\%) - 7 (8,6\%)^{\P} \\ \hline IIIB & 2 (2,4\%) \\ \hline \end{array}$	Preoperative Therapy	Combined Therapy	17 (21%)
$\frac{Cyclosporine}{Free prevention of the system of the sys$		Biologics	26 (32%)
$\begin{tabular}{llll} & Haemoglobin (g/dL) & 10,3 \pm 1,99 \\ & White Cell Count (u/L) & 9411 \pm 3670 \\ & C Reactive Protein (mg/dL) & 41,2 \pm 45,7 \\ & Total Proteins (g/L) & 5,56 \pm 0,85 \\ & Albumin (g/L) & 28 \pm 6,7 \\ & Transthyretine (g/L) & 0,14 \pm 0,05 \\ \hline & Refractory to Medical Therapy & 26 (32,1%) \\ \hline & Indication for Surgery & Severe Acute Colitis & 47 (58%) \\ & Toxic Megacolon & 8 (9,9%) \\ \hline & Operative Time (minutes) & 211 \pm 60,6 \\ \hline & Conversion Rate & 3 (3,7\%) \\ \hline & Specimen Delivery & Stoma Site & 42 (51,8\%) \\ \hline & Peri-umbilical & 2 (2,6\%) \\ \hline & Grade I+II & 47 (58\%) - 7 (8,6\%)^{\P} \\ \hline & IIIA & 3 (3,8\%) \\ \hline & Complications (Clavien-Dindo) & IIIB & 2 (2,4\%) \\ \hline \end{array}$		Cyclosporine	7 (8,8%)
$\begin{array}{c} \mbox{Preoperative Blood Exams} & \begin{tabular}{llll} White Cell Count (u/L) & 9411 \pm 3670 \\ C \ Reactive Protein (mg/dL) & 41,2 \pm 45,7 \\ Total Proteins (g/L) & 5,56 \pm 0,85 \\ Albumin (g/L) & 28 \pm 6,7 \\ Transthyretine (g/L) & 0,14 \pm 0,05 \\ \hline & Refractory to Medical Therapy & 26 (32,1\%) \\ Indication for Surgery & Severe Acute Colitis & 47 (58\%) \\ Toxic Megacolon & 8 (9,9\%) \\ \hline & Operative Time (minutes) & 211 \pm 60,6 \\ \hline & Conversion Rate & 3 (3,7\%) \\ \hline & Suprapubic Incision & 37 (45,6\%) \\ Specimen Delivery & Stoma Site & 42 (51,8\%) \\ \hline & Peri-umbilical & 2 (2,6\%) \\ \hline & Grade I+II & 47 (58\%) - 7 (8,6\%)^{1} \\ \hline & IIIA & 3 (3,8\%) \\ \hline & Complications (Clavien-Dindo) & IIIB & 2 (2,4\%) \\ \hline \end{array}$		Haemoglobin (g/dL)	10,3 ± 1,99
Preoperative Blood ExamsC Reactive Protein (mg/dL) Total Proteins (g/L) Albumin (g/L) $41,2 \pm 45,7$ $5,56 \pm 0,85$ $41,2 \pm 6,7$ Transthyretine (g/L)Indication for SurgeryRefractory to Medical Therapy Severe Acute Colitis $26 (32,1\%)$ Indication for SurgerySevere Acute Colitis Toxic Megacolon $47 (58\%)$ $3 (3,7\%)$ Operative Time (minutes) $211 \pm 60,6$ Conversion Rate $3 (3,7\%)$ Specimen DeliveryStoma Site Peri-umbilical $42 (51,8\%)$ Peri-umbilicalComplications (Clavien-Dindo)IIIB IIIB $2 (2,4\%)$		White Cell Count (u/L)	9411 ± 3670
Preoperative block ExamsTotal Proteins (g/L) $5,56 \pm 0,85$ Albumin (g/L) $28 \pm 6,7$ Transthyretine (g/L) $0,14 \pm 0,05$ Refractory to Medical Therapy $26 (32,1\%)$ Indication for SurgerySevere Acute ColitisToxic Megacolon $8 (9,9\%)$ Operative Time (minutes) $211 \pm 60,6$ Conversion Rate $3 (3,7\%)$ Specimen DeliveryStoma SitePeri-umbilical $2 (2,6\%)$ Grade I+II $47 (58\%) - 7 (8,6\%)^{\P}$ IIIA $3 (3,8\%)$ Complications (Clavien-Dindo)IIIBVV	Prophorative Plead Evams	C Reactive Protein (mg/dL)	41,2 ± 45,7
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Preoperative Blood Exams	Total Proteins (g/L)	5,56 ± 0,85
$\begin{tabular}{ c c c c c c } \hline Transthyretine (g/L) & 0,14 \pm 0,05 \\ \hline Refractory to Medical Therapy & 26 (32,1%) \\ \hline Refractory to Medical Therapy & 26 (32,1%) \\ \hline Severe Acute Colitis & 47 (58%) \\ \hline Toxic Megacolon & 8 (9,9%) \\ \hline Operative Time (minutes) & 211 \pm 60,6 \\ \hline Conversion Rate & 3 (3,7%) \\ \hline Conversion Rate & 3 (3,7%) \\ \hline Suprapubic Incision & 37 (45,6%) \\ Specimen Delivery & Stoma Site & 42 (51,8%) \\ \hline Peri-umbilical & 2 (2,6%) \\ \hline Grade I+II & 47 (58%) - 7 (8,6%)^{1} \\ \hline IIIA & 3 (3,8%) \\ \hline Complications (Clavien-Dindo) & IIIB & 2 (2,4%) \\ \hline \end{tabular}$		Albumin (g/L)	28 ± 6,7
Refractory to Medical Therapy26 (32,1%)Indication for SurgerySevere Acute Colitis47 (58%)Toxic Megacolon8 (9,9%)Operative Time (minutes)211 ± 60,6Conversion Rate3 (3,7%)Suprapubic Incision37 (45,6%)Specimen DeliveryStoma SitePeri-umbilical2 (2,6%)Grade I+II47 (58%) – 7 (8,6%)IIIA3 (3,8%)Complications (Clavien-Dindo)IIIBIV/		Transthyretine (g/L)	0,14 ± 0,05
Indication for SurgerySevere Acute Colitis Toxic Megacolon47 (58%) 8 (9,9%)Operative Time (minutes)211 ± 60,6Conversion Rate3 (3,7%)Suprapubic Incision37 (45,6%)Specimen DeliveryStoma Site Peri-umbilicalGrade I+II47 (58%) – 7 (8,6%)IIIA3 (3,8%)Complications (Clavien-Dindo)IIIBIV/	Previous Abdominal Surgery Preoperative Therapy Preoperative Blood Exams Indication for Surgery Operative Time (minutes) Conversion Rate Specimen Delivery	Refractory to Medical Therapy	26 (32,1%)
Toxic Megacolon 8 (9,9%) Operative Time (minutes) 211 ± 60,6 Conversion Rate 3 (3,7%) Suprapubic Incision 37 (45,6%) Specimen Delivery Stoma Site 42 (51,8%) Peri-umbilical 2 (2,6%) Grade I+II 47 (58%) – 7 (8,6%) [¶] IIIA 3 (3,8%) Complications (Clavien-Dindo) IIIB 2 (2,4%)		Severe Acute Colitis	47 (58%)
		Toxic Megacolon	8 (9,9%)
Conversion Rate 3 (3,7%) Suprapubic Incision 37 (45,6%) Specimen Delivery Stoma Site 42 (51,8%) Peri-umbilical 2 (2,6%) Grade I+II 47 (58%) – 7 (8,6%) [¶] IIIA 3 (3,8%) Complications (Clavien-Dindo) IIIB 2 (2,4%)	Operative Time (minutes)		211 ± 60,6
Suprapubic Incision 37 (45,6%) Specimen Delivery Stoma Site 42 (51,8%) Peri-umbilical 2 (2,6%) Grade I+II 47 (58%) – 7 (8,6%) IIIA 3 (3,8%) Complications (Clavien-Dindo) IIIB IV /	Conversion Rate		3 (3,7%)
Specimen Delivery Stoma Site 42 (51,8%) Peri-umbilical 2 (2,6%) Grade I+II 47 (58%) – 7 (8,6%) [¶] IIIA 3 (3,8%) Complications (Clavien-Dindo) IIIB 2 (2,4%)		Suprapubic Incision	37 (45,6%)
Peri-umbilical 2 (2,6%) Grade I+II 47 (58%) - 7 (8,6%) [¶] IIIA 3 (3,8%) Complications (Clavien-Dindo) IIIB 2 (2,4%)	Specimen Delivery	Stoma Site	42 (51,8%)
Grade I+II 47 (58%) - 7 (8,6%)¶ IIIA 3 (3,8%) Complications (Clavien-Dindo) IIIB 2 (2,4%)		Peri-umbilical	2 (2,6%)
Complications (Clavien-Dindo) IIIB 2 (2,4%)		Grade I+II	47 (58%) – 7 (8,6%) [¶]
Complications (Clavien-Dindo) IIIB 2 (2,4%)	Complications (Clavien-Dindo)	IIIA	3 (3.8%)
		IIIB	2 (2,4%)
IV /		IV	
V 1 (1.2%)		V	1 (1.2%)
Readmission (90 days) 11 (13.5%)	Readmission (90 days)	-	11 (13.5%)
Beoperation (90 days) 6 (7 4%)	Reoperation (90 days)		6 (7 4%)
Hospitalisation (days) 15.2 ± 7.8	Hospitalisation (days)		152+78

Table 2. Patients submitted to completion proctectomy or proctocolectomy with pouch construction and IPAA (the following parameters relate to the 1st stage: ASA Score[¶], medical therapy[†], readmission and reoperation^{*}; summation of 1st and 2nd stage operative times [§]; Clavien-Dindo's stages I and II excluding perioperative blood transfusion and TPN[#]; considering only Clavien-Dindo's stages III-V[‡]; and hospitalisation[^]).

	Completion Pro	octectomy n 71	Proctocolectomy n 79	p value
Age	42,6 ± 15,5		51,3 ± 14	0,0001
Gender				
Males	42 (59,1%)		50 (63,3%)	
Females	29 (40,9%)		29 (36,7%)	0,72
Extra-intestinal Manifestations of IBD	8 (11,2%)		5 (6,9%)	0,43
Familiarity for IBD	4 (5,6%)		7 (8,8%)	0,65
Smoking Habit	6 (8,4%)		6 (7,5%)	0,92
Diagnosis	,			•
Ulcerative Colitis	66 (92,9%)		77 (97,4%)	
Crohn's Disease	2 (2,8%)		2 (2,6%)	
Indeterminate Colitis	3 (4,3%)		0	0,28
Age at Diagnosis (years)	36,5 ± 15		37,8 ± 16,3	0,6
Disease Duration (years)	6 ± 6,4		13,6 ± 9,1	0,0001
ASA Score				· · ·
ASA1	30 (42,2%)	10 (12,3%) [¶]	11 (13,9%) [¶]	
ASA2	40 (56,4%)	61 (75,3%) [¶]	58 (73,4%)¶	
ASA3	1 (1,4%)	10 (12,4%) [¶]	10 (12,7%) [¶]	0,0007 - 0,9 [¶]
Previous Abdominal Surgery	6 (8,4%)		13 (16,4%)	0,22
Preoperative Therapy				
5-ASA	/	5 (6,2%)†	13 (16,4%)	
Steroids	/	26 (32%)+	15 (18,9%)	
Combined Therapy	/	17 (21%)†	16 (20,2%)	
Biologics	/	26 (32%)+	21 (26,5%)	
Cyclosporin	/	7 (8,8%)†	1 (1,6%)	0,03
Preoperative Blood Exams				
Haemoglobin (g/dL)	12,9 ± 1,2		12,23 ± 2,07	0,7
C Reactive Protein (mg/dL)	2 ± 1,3		13,7 ± 25,8	0,0002
Total Proteins (g/L)	6,8 ± 0,96		6,35 ± 0,89	0,003
Albumin (g/L)	4 ± 0,78		3,5 ± 0,7	0,0001
Transthyretine (g/L)	0,22 ± 0,03		0,20 ± 0,05	0,003
Operative Time (minutes)	186,6 ± 56,7	352 ± 91,5 [§]	325,75 ± 86,25 [§]	0,07 [§]
IPAA				
Hand sewn	2 (2,9%)		5 (6,4%)	
Stapled	69 (97,1%)		74 (93,6%)	0,44
Conversion Rate	2 (2,8%)		1 (1,6%)	0,6
Specimen Delivery				
Suprapubic Incision	30 (42,2%)		41 (51,9%)	
Stoma Site	40 (56,4%)		36 (45,5%)	
Peri-umbilical	1 (1,4%)		2 (2,6%)	0,43
Complications (Clavien-Dindo)				
Grade I+II	3 (4,3%)		26 (32,9%) – 5 (6,3%)#	
IIIA	2 (1,4%)		2 (2,6%)	
IIIB	2 (1,4%)		5 (6,3%)	
IV	/	4 (5,6%)‡	1 (1,2%) 8 (10,1%)‡	0,0001 - 0,89‡
Defunctioning Ileostomy	66 (92,9%)		72 (91,1%)	0,92
IPAA leakage	2 (2,9%)		4 (5%)	0,68
Pouch Leakege	1 (1,4%)		1 (1,6%)	1
Readmission (90 days)	2 (2,9%)	11 (13,5%)*	10 (12,7%)*	0,03 - 1*
Reoperation (90 days)	1 (1,4%)	6 (7,4%)*	8 (10,1%)*	0,03 - 0,58*
Hospitalisation (days)	9,1 ± 3,2	15,2 ± 7,8 [^]	13,9 ± 7,2^	0,0001 - 0,2

Table 3. Patients submitted to ileostomy closure after 2 or 3 stages procedure.

	3-stages n 66	2-stages n 70	p value	
Gender				
Males	42 (63.6%)	46 (65.7%)		
Females	24 (36.4%)	24 (34.3%)	0,9	
ASA Score				
ASA1	30 (45.5%)	10 (14.2%)		
ASA2	36 (54.5%)	52 (74.2%)		
ASA3	0	8 (11.6%)	0,0001	
Previous Abdominal Surgery	6 (9%)	11 (15.7%)	0,03	
Complications (Clavien-Dindo)				
Grade I+II	1 (1.5%)	3 (4.3%)		
IIIA	0	0		
IIIB	0	3 (4.3%)	0,1	
Readmission (90 days)	1 (1.5%)	1 (1.4%)	1	
Reoperation (90 days)	1 (1.5%)	1 (1.4%)	1	
Hospitalisation (days)	6,6 ± 4,4	9.2 ± 4.6	0,0001	



Figure 1. Trocar positioning and ports utilisation during 1st and 2nd stage.



Figure 2. Upper panel: Kaplan-Meier time-to-event estimates of Pouch Failure (left) and Permanent Ileostomy (right). Lower panel: Kaplan-Meier time-to-event estimates of first episode of Pouchitis (left) and functional results (right)